000			01763nam a2200421 i 4500
999			_c276859 _d276859
001			on1057362064
003			OCoLC
005			20190110131807.0
006			m o d f
007			cr bn||||a||||
008			181018s2018 dcua ob f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dMvI
042			_apcc
043			_an-us---
074			_a1037-D (online)
086	0		_aY 4.G 74/9:F 36
099			_aY 4.G 74/9:F 36
110	1		_aUnited States. _bCongress. _bSenate. _bCommittee on Homeland Security and Governmental Affairs,
245	1	0	_aFueling an epidemic, report four : _binside the Insys strategy for boosting fentanyl sales / _cU.S. Senate Homeland Security & Governmental Affairs Committee, Ranking Member's Office.
246	3	0	_aInside the Insys strategy for boosting fentanyl sales
264		1	_a[Washington, D.C.] : _bCommittee on Homeland Security and Governmental Affairs, _c[2018]
300			_a1 online resource (35, [159] pages) : _bcolor illustrations
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
500			_aAt head of title: HSGAC minority staff report.
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
588			_aDescription based on online resource; title from PDF title screen (HSGAC web site, viewed on Oct. 18, 2018).
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo110284
610	2	0	_aInsys Therapeutics, Inc.
650		0	_aFentanyl _zUnited States.
650		0	_aOpioid abuse _zUnited States.
650		0	_aFentanyl _xOverdose _zUnited States.
650		0	_aDrugs _zUnited States _xMarketing.
650		0	_aPharmaceutical industry _xCorrupt practices _zUnited States.
942			_2sudocs _c8